Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2012, Article ID 832974, 10 pages
http://dx.doi.org/10.1155/2012/832974
Clinical Study

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA  >20 ng/mL

1Clinic of Urology, Department of Surgery, “St. Marina” University Hospital, Hr. Smirnenski Street 1, 9010 Varna, Bulgaria
2Department of Statistics, University of Economics, 9010 Varna, Bulgaria

Received 15 February 2012; Revised 29 May 2012; Accepted 31 May 2012

Academic Editor: Harry J. Wanebo

Copyright © 2012 Alexander I. Hinev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Eggener, K. A. Roehl, N. D. Smith, J. A. V. Antenor, M. Han, and W. J. Catalona, “Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy,” The Journal of Urology, vol. 173, no. 4, pp. 1150–1155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. H. M. Lee, M. J. Solan, P. Lupinacci, L. G. Gomella, and R. K. Valicenti, “Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy,” Urology, vol. 64, no. 1, pp. 84–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Gontero, G. Marchioro, R. Pisani et al., “Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study,” European Urology, vol. 51, no. 4, pp. 922–930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. I. Hinev, A. Klissarova, P. Ghenev et al., “Radioisotopic detection of sentinel lymph nodes in clinically localized high-risk prostate cancer,” Journal of the Balkan Union of Oncology, vol. 14, no. 4, pp. 661–667, 2009. View at Google Scholar · View at Scopus
  5. S. J. Freedland, L. A. Mangold, P. C. Walsh, and A. W. Partin, “The prostatic specific antigen era is alive and well: prostatic specific-antigen and biochemical progression following radical prostatectomy,” The Journal of Urology, vol. 174, no. 4, part 1, pp. 1276–1281, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. I. Hinev, “The pros and cons of prostate-specific antigen testing,” Biomedical Reviews, vol. 12, no. 1, pp. 57–63, 2001. View at Google Scholar · View at Scopus
  7. A. V. D'Amico, A. A. Renshaw, K. Cote et al., “Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3726–3732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. C. J. Diblasio and M. W. Kattan, “Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer,” Urology, vol. 62, supplement 1, pp. 9–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. A. W. Partin, M. W. Kattan, E. N. P. Subong et al., “Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update,” The Journal of the American Medical Association, vol. 277, no. 18, pp. 1445–1451, 1997. View at Google Scholar · View at Scopus
  10. S. A. Boorjian, R. J. Karnes, L. J. Rangel, E. J. Bergstralh, and M. L. Blute, “Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy,” The Journal of Urology, vol. 179, no. 4, pp. 1354–1361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. Stephenson, P. T. Scardino, J. A. Eastham et al., “Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy,” Journal of the National Cancer Institute, vol. 98, no. 10, pp. 715–717, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. W. Hull, F. Rabbani, F. Abbas, T. M. Wheeler, M. W. Kattan, and P. T. Scardino, “Cancer control with radical prostatectomy alone in 1,000 consecutive patients,” The Journal of Urology, vol. 167, no. 2, part 1, pp. 528–534, 2002. View at Google Scholar · View at Scopus
  13. C. Bastide, R. Kuefer, M. Loeffler, R. de Petriconi, J. Gschwend, and R. Hautmann, “The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level > 20 ng/ml,” Prostate Cancer and Prostatic Diseases, vol. 9, no. 3, pp. 239–244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. W. Brandli, M. O. Koch, R. S. Foster et al., “Biochemical disease-free survival in patients with a high prostate-specific antigen level (20–100 ng/mL) and clinically localized prostate cancer after radical prostatectomy,” BJU International, vol. 92, no. 1, pp. 19–23, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. F. O'Brien, S. S. Connolly, D. G. Kelly, A. O'Brien, D. M. Quinlan, and D. W. Mulvin, “Should patients with a pre-operative prostate-specific antigen greater than 15 ng/ml be offered radical prostatectomy?” Irish Journal of Medical Science, vol. 173, no. 1, pp. 23–26, 2004. View at Google Scholar · View at Scopus
  16. R. Frota, B. Turna, B. M. R. Santos, Y. C. Lin, I. S. Gill, and M. Aron, “The effect of prostate weight on the outcomes of laparoscopic radical prostatectomy,” British Journal of Urology International, vol. 101, no. 5, pp. 589–593, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. B. P. Vanasupa, E. L. Paquette, H. Wu, L. Sun, D. G. McLeod, and J. W. Moul, “The role of radical prostatectomy in patients with pretreatment prostate-specific antigen ≥ 40 ng/mL,” Urologic Oncology, vol. 7, no. 4, pp. 167–172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. U. Zwergel, H. Suttmann, T. Schroeder et al., “Outcome of prostate cancer patients with initial PSA ≥ 20 ng/ml undergoing radical prostatectomy,” European Urology, vol. 52, no. 4, pp. 1058–1066, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Walz, S. Joniau, F. K. Chun et al., “Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy,” British Journal of Urology International, vol. 107, no. 5, pp. 765–770, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Briganti, S. Joniau, P. Gontero et al., “Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer,” European Urology, vol. 61, no. 3, pp. 584–592, 2012. View at Publisher · View at Google Scholar
  21. P. J. Bastian, S. A. Boorjian, A. Bossi et al., “High-risk prostate cancer: from definition to contemporary management,” European Urology, vol. 61, no. 6, pp. 1096–1106, 2012. View at Publisher · View at Google Scholar
  22. A. Gallina, C. Jeldres, F. K. H. Chun et al., “Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL,” European Urology, vol. 52, no. 5, pp. 1374–1380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. G. Sanda, R. L. Dunn, J. Michalski et al., “Quality of life and satisfaction with outcome among prostate-cancer survivors,” The New England Journal of Medicine, vol. 358, no. 12, pp. 1250–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Bolla, H. van Poppel, L. Collette et al., “Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911),” The Lancet, vol. 366, no. 9485, pp. 572–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Ost, V. Fonteyne, G. Villeirs, N. Lumen, W. Oosterlinck, and G. De Meerleer, “Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients,” European Urology, vol. 56, no. 4, pp. 669–677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Parker, N. Clarke, J. Logue et al., “RADICALS (radiotherapy and androgen deprivation in combination after local surgery),” Clinical Oncology, vol. 19, no. 3, pp. 167–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. I. M. Thompson, C. M. Tangen, J. Paradelo et al., “Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial,” The Journal of Urology, vol. 181, no. 3, pp. 956–962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Vargas, L. L. Kestin, D. W. Weed, D. Krauss, F. A. Vicini, and A. A. Martinez, “Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features,” International Journal of Radiation Oncology, Biology, Physics, vol. 61, no. 3, pp. 714–724, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. A. I. Hinev, in Pelvic Lymph Node Dissection and Radical Prostatectomy in Prostate Cancer, p. 208, Faber, Veliko Tarnovo, Bulgaria, 2012.
  30. K. Nguyen, S. Eltz, S. J. Drouin et al., “Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience,” World Journal of Urology, vol. 27, no. 5, pp. 653–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Xylinas, S. J. Drouin, E. Comperat et al., “Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience,” British Journal of Urology International, vol. 103, no. 9, pp. 1173–1178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Paul, M. Fourmarier, C. Cordonnier, J. Petit, J. Petit, and F. Saint, “High PSA and total prostatectomy: specific and overall 10-year survival,” Progrès en Urologie, vol. 18, no. 5, pp. 299–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. B. N. Bloch, E. Furman-Haran, T. H. Helbich et al., “Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging—initial results,” Radiology, vol. 245, no. 1, pp. 176–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau, and L. Lemaitre, “Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings,” The Journal of Urology, vol. 176, no. 6, part 1, pp. 2432–2437, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. D. Shelley, S. Kumar, T. Wilt, J. Staffurth, B. Coles, and M. D. Mason, “A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma,” Cancer Treatment Reviews, vol. 35, no. 1, pp. 9–17, 2009. View at Publisher · View at Google Scholar · View at Scopus